tbuckley/cabot-search huggingface dataset:
ASIATIC RELAPSING FEVER; REPORT OF 134 CASES TREATED WITH MAPHARSEN
Authors: Bernard P. Wolff
Journal: Annals of Internal Medicine (1946)

Article1 February 1946ASIATIC RELAPSING FEVER; REPORT OF 134 CASES TREATED WITH MAPHARSENBERNARD P. WOLFFBERNARD P. WOLFFSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-24-2-203 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis report comprises 134 cases of relapsing fever of the Asiatic type. Relapsing fever is a spirochetal infection characterized by one or more attacks of fever beginning and ending abruptly and separated by an afebrile period of varying duration.The disease is prevalent in many parts of the world and assumes the form of a virulent epidemic in famine stricken, debilitated populations. The causative organism is a spirochete of the genusSpirochaeta(Borrelia) and transmission is by infected lice or ticks. The spirochetes of relapsing fever have been separated by agglutination and other reactions into two groups—S. recurrentis(louse-borne), and...Bibliography1. STRONG RP: Stitt's diagnosis, prevention of tropical disease, 1943, The Blakiston Co., Philadelphia, Vol. I, p. 321. Google Scholar2. BERGEY DH: Bergey's manual of determinative bacteriology, 1939, The Williams & Wilkins Co., Baltimore, pp. 951-955. Google Scholar3. STRONG RP: Stitt's diagnosis, prevention of tropical disease, 1943, The Blakiston Co., Philadelphia, Vol. I, p. 354. Google Scholar4. STRONG RP: Stitt's diagnosis, prevention of tropical disease, 1943, The Blakiston Co., Philadelphia, Vol. I, p. 352. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication June 4, 1945. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLouse-borne relapsing fever—A systematic review and analysis of the literature: Part 1—Epidemiology and diagnostic aspectsLouse-borne relapsing fever—A systematic review and analysis of the literature: Part 2—Mortality, Jarisch–Herxheimer reaction, impact on pregnancySpirochaetal infections of the nervous systemMEPTAZINOL DIMINISHES THE JARISCH-HERXHEIMER REACTION OF RELAPSING FEVERReaction following treatment of murine borreliosis and Shwartzman type reaction with borrelial sonicatesLouse-borne relapsing fever: I. A clinical and laboratory study of 363 cases in the SudanLouse-borne relapsing fever: II. Combined penicillin and tetracycline therapy in 160 Sudanese patientsChemotherapy of Spirochetal InfectionsPathogenesis of the Jarisch-Herxheimer Reaction: A REVIEW OF CLINICAL AND EXPERIMENTAL OBSERVATIONS 1 February 1946Volume 24, Issue 2Page: 203-216KeywordsFeversLicePopulation statisticsRelapsing feverSpirochaetales InfectionsSpirochetesStarvationTicks ePublished: 1 December 2008 Issue Published: 1 February 1946 PDF downloadLoading ...
In vivo modulation with anti-interleukin-1 (IL-1) receptor (p80) antibody 35F5 of the response to IL-1. The relationship of radioprotection, colony-stimulating factor, and IL-6
Authors: R Neta, SN Vogel, JM Plocinski, NS Tare, W Benjamin, R Chizzonite, M Pilcher
Journal: Blood (1990)
Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas
Authors: D. Terhorst, D.S. Mestel, D. Humme, W. Sterry, M. Beyer
Journal: British Journal of Dermatology (2012)

Primary cutaneous lymphomas (CLs) are a heterogeneous group of diseases arising from B or T lymphocytes. CLs are grouped according to their clinical behaviour into indolent, intermediate and aggressive types. Indolent CLs respond well to therapy but frequently relapse, resulting in prolonged periods of follow-up.To evaluate the outcome of follow-up examinations in indolent CL.We retrospectively analysed a cohort from a CL outpatient clinic at a tertiary referral centre. Seventy-five patients with indolent cutaneous T-cell lymphomas (CTCLs) and 34 patients with indolent cutaneous B-cell lymphomas (CBCLs) were included. The value of clinical examination, blood tests and imaging procedures for detection of recurrence or progression was assessed.In patients with CTCL all but one disease recurrences were detected by clinical examination. Lymph node or organ involvement was detected by imaging procedures in seven patients, of whom all but one had recurrent or persistent CL lesions. In CBCL all recurrences were detected by clinical examination.Patients with indolent CL confined to the skin should be followed primarily by clinical examination. However, in patients who are refractory to treatment regular screening of lymph nodes by ultrasound may enable earlier detection of disease recurrence or progression.
Amino Acid Incorporation by in Vitro Tumor and Liver Systems and Their Response to Exogenous Ribonucleic Acid
Authors: M. A. O'Neal, A. C. Griffin
Journal: Cancer Research (1963)

A procedure is described for the isolation of amino acid-incorporating systems from Novikoff ascites tumor and from rat liver. Under the conditions employed the tumor system will incorporate approximately 30–70 µµmoles of amino acid/mg ribosomal protein when C14-labeled valine, phenylalanine, or lysine is added to the incubation medium. Addition of ribonucleic acid preparations from tumor and liver nuclei, tumor ribosomes, or tobacco mosaic virus to the tumor amino acid-incorporating system caused a 16–45 per cent increase in amino acid incorporation. Addition of polyuridylic acid to the tumor system with C14-l-phenylalanine caused a seven- to tenfold increase in the incorporation of this amino acid. These findings indicate that this mammalian system responds to the same nucleotide coding sequence for phenylalanine as E. coli and provide evidence that the tumor-incorporating system will respond to a limited extent to natural ribonucleic acids and to synthetic polynucleotides.
From early to advanced COPD: What differences in balance and risk of falling?
Authors: Cristina Jácome, Joana Cruz, Raquel Gabriel, Daniela Figueiredo, Alda Marques
Journal: European Respiratory Journal (2013)

Patients with COPD have impaired balance and high risk of falling. However, this was only explored in advanced COPD. This study aimed to assess balance and risk of falling considering all COPD grades and explore the predictors of risk of falling. A cross-sectional study with 106 outpatients with COPD was conducted. Spirometry was first performed. Anxiety and depression were assessed with the Hospital Anxiety and Depression Scale and functional limitations due to dyspnoea with the Modified British Medical Research Council questionnaire (mMRC). Balance and risk of falling were determined using the Timed Up and Go test (TUG). Descriptive and inferential statistics were applied. On average, participants (age 72.1±8.5yrs; FEV 1  62.7±24.1%predicted) performed the TUG in 11±4.8s. A total of 46 (43.4%) participants had a TUG performance worse than reference values of age-matched healthy peers. Risk of falling (TUG≥13.5s) was significantly higher in participants with severe to very severe COPD (45.7%) comparing with those with mild (5.9%) and moderate (18.9%) COPD (p=0.001). Participants at risk of falling were older (p=0.002), had a lower FEV 1 %predicted (p=0.001), a higher mMRC score (p=0.049) and more depression symptoms (p=0.008) than those at no risk of falling. Age (OR 1.1; 95%CI=1.03-1.16) and depression symptoms (OR 1.2; 95%CI=1.08-1.40) were significant predictors of risk of falling. Balance impairment and risk of falling are already present at early COPD, although more evident at advanced grades. These findings highlight the importance of balance assessment in patients at all COPD grades and the inclusion of balance training and fall prevention strategies as part of Pulmonary Rehabilitation.
Geriatric medicine: a brief history
Authors: J. G. Evans
Journal: BMJ (1997)

Old age has always been with us.The ancient Egyptians and the author of the 12th chapter of Ecclesiastes were familiar with the common disabilities of later life.Survival into what we still regard as old age was not unusual in classical Greece (table).The average length of human life has increased over the centuries as living conditions have improved and childhood mortality has fallen; the maximum lifespan of our species is determined largely by our genes and will be the same as it ever was.Doctors and philosophers of antiquity commented on age associated illness.Hippocrates noted conditions common in later life, and Aristotle offered a theory of aging based on loss of heat.Two thousand years were to pass before anything better was written on the subject.Francis Bacon proposed a scientific programme of epidemiological investigations into the longevity of people living in different places and under different conditions. 1 He also noted that the pursuit of knowledge depended on "the fresh examination of particulars," advice that underlaid the systematic observation of nature that complemented the active experimentation advocated by his contemporary William Harvey.During the 18th and 19th centuries several physicians wrote specifically about the diseases of later life and their treatment.These included Cheyne 2 and Day 3 in Britain and Rush 4 in the United States.Charcot's lectures on the medicine of old age aroused scientific interest in the field and became available in English translation in 1881. 5 The word "geriatrics" was invented by Ignatz L Nascher, a Vienna-born immigrant to the United States in 1909. 6(It is not clear who is to blame for the barbarous miscoining of "gerontology"-the study of old men-for "geratology"-the study of old age.)Nascher's initiative provided a stimulus for social and biological research on aging, 7 but clinical geriatrics did not flourish in the United States.The American Geriatrics Society was founded in 1942, but as a thriving and influential medical specialty geriatric medicine was essentially a product of the British NHS. Old age in classical Greece
A memorable patient: Just being there
Authors: A. Matalon
Journal: BMJ (2001)

I joined the clinic three years ago and I was to collect my list from patients who were discontented at how inaccessible they found their former family doctors. One of these patients was Zohara (in Hebrew: the illuminated). She had passed from one doctor to another and now she was to try me. She was a Yemenite widow aged about 68 who often visited the clinic, although she didn't suffer from any chronic disorder other than abdominal pain. She had had countless consultations, visits to emergency departments, ultrasound examinations, endoscopies, and barium enemas, but the cause of the pain could not be found. Psychiatric consultations suggested masked depression but couldn't help her, or me, any further. All medications were ineffective.

After nearly three years of frustration, here she came again at the end of …
Abstract 19776: Angioscopic Comparison of Arterial Repair Between Biodegradable Polymer-Coated Biolimus A9-Eluting Stent and Durable Polymer-Coated Sirolimus-Eluting Stent in Patients
Authors: Masaki Awata, Fusako Sera, Takayuki Ishihara, Tetsuya Watanabe, Masashi Fujita, Osamu Iida, Okamoto Shin, Nobuaki Tanaka, Tomoharu Dohi, Tsuyoshi Mishima, Yukika Mizugami, Kiyonori Nanto, Yoshio Ishida, Shinsuke Nanto, Masaaki Uematsu, Seiki Nagata
Journal: Circulation (2010)

Background: Biodegradable polymer-coated biolimus A9-eluting stent (BES)(Terumo Corporation, Japan) are expected to show better arterial repair than first-generation DES. Thus, using angioscopy (Ve...
Evaluation of Suspected Adverse Drug Reactions—Reply
Authors: Brian L. Strom
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sphingosine-1-phosphate (S1P) as a potential biomarker for multiple myeloma: determination of plasma S1P by ELISA using a monoclonal antibody to S1P.
Authors: Masao Hiraiwa, Kelli Moreno, Rosalia Matteo, Brad Cunningham, Shmuel Yaccoby, Genevieve Hansen, Roger Sabbadini
Journal: Clinical Cancer Research (2008)

B11   This study was undertaken to use a recently-developed ELISA-based assay to evaluate plasma sphingosine-1-phosphate (S1P) as a potential biomarker for malignant myeloma (MM). The bioactive lipid signaling mediator, S1P, is the only product of an oncogene, sphingosine kinase1 (Sphk1), and is S1P is known to promote tumorigenesis and angiogensis. S1P is produced by cancer cells for release into the extracellular space to activate its cognate GPCRs. While S1P has been proposed as a cancer biomarker, but a simple, inexpensive assay for its measurement as not been available until now. We have generated a monoclonal antibody (mAb) that has been shown to retard tumor progression in experimental animals (Visentin et al. 2006), and report here that it can be used to assess S1P as a biomarker in the plasma of cancer patients. The detection limit, assay linearity, and inter- and intra-assay precision were satisfactory for the assay development and optimization. The S1P ELISA operates in a dynamic range from 10 pM to 2 uM S1P. S1P level in cancer-free, control human plasma was 0.215 ± 0.094 uM (n=41). Importantly, the plasma S1P levels were significantly (p
SULFAPYRIDINE THERAPY IN PNEUMONIA: A DISCUSSION OF APPARENT FAILURES AND COMPLICATIONS
Authors: Frank Edward Smith, Richard Riley, Oswald R. Jones
Journal: Annals of Internal Medicine (1940)

Article1 December 1940SULFAPYRIDINE THERAPY IN PNEUMONIA: A DISCUSSION OF APPARENT FAILURES AND COMPLICATIONSFRANK EDWARD SMITH JR., M.D., RICHARD RILEY, M.D., OSWALD R. JONES, M.D., F.A.C.P.FRANK EDWARD SMITH JR., M.D.Search for more papers by this author, RICHARD RILEY, M.D.Search for more papers by this author, OSWALD R. JONES, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-6-1032 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONA review of a series of 122 ward and private cases of pneumonia treated with sulfapyridine at St. Luke's Hospital from November 15, 1938 to April 15, 1939 revealed that there were eight deaths in the series, or a mortality of 6.5 per cent. In addition to these eight cases, it was noted that there were seven patients who, although they survived their pneumonia, failed to show a good clinical response to this form of chemotherapy. Believing that a detailed summary of these 15 cases would be of interest at this time, we are presenting the following summaries, after...Bibliography1. LÖFSTRÖM G: Serologic studies in acute pneumonia, Hygeia, 1939, ii, 1927. Google Scholar2. WOODLONG BPH: Mechanism of recovery from pneumococcus pneumonia in patients treated with sulfapyridine, ANN. INT. MED., 1939, xiii, 612. Google Scholar3. LONGWOOD PHB: Therapy of pneumococcal pneumonia with sulfapyridine, ANN. INT. MED., 1939, xiii, 487. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication November 16, 1939.From Medical Division A, Dr. George M. Goodwin, Senior Attending Physician, St. Luke's Hospital, New York City. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCommunicable Diseases and Military Medicine 1 December 1940Volume 14, Issue 6Page: 1032-1041KeywordsChemotherapyMortalityPediatric surgeryPediatricsPneumonia ePublished: 1 December 2008 Issue Published: 1 December 1940 PDF downloadLoading ...
One Mutation Fits All: Phospholamban R14del Causes Both Dilated Cardiomyopathy and Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
Authors: Paul A. van der Zwaag, Maarten P. van den Berg, Moniek G. Cox, Rudolf A. de Boer, Karin Y. van Spaendonck-Zwarts, Robert M. Hofstra, Ans C. Wiesfeld, Richard N. Hauer, Arthur A. Wilde, Jan D. Jongbloed, J. P. van Tintelen
Journal: Circulation (2010)

Introduction: Comprehensive screening of genes encoding desmosomal proteins identifies a mutation in 40%-60% of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) patients. Although...
Abstract 649: Development and preclinical characterization of an Fc-optimized CD133 antibody for improved induction of NK cell reactivity against myeloid leukemia
Authors: Samuel Koerner, Julia Leibold, Ludger Grosse-Hovest, Hans-Jörg Bühring, Helmut R. Salih, Gundram Jung
Journal: Cancer Research (2014)

Abstract NK cells are cytotoxic lymphocytes that play a major role in anti-tumor immunity and largely contribute to the efficacy of allogenic stem cell transplantation (SCT) in leukemia. Another clinically important feature of NK cells is their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) upon application of anti-tumor antibodies (mAb) such as Rituximab. Modifications of the human IgG1 Fc-part of anti-tumor antibodies may lead to markedly improved capability to recruit Fc-receptor bearing effector cells. Here we report on the development and preclinical characterization of an Fc-optimized mAb directed towards CD133, a molecule expressed on a wide variety of malignant cell types. Initially we evaluated binding of three different mouse anti-human CD133 mAbs (clones AC133, W6B3 and 293C3) to 20 AML and 6 CML samples to identify a clone with optimal binding characteristics. Binding of AC133 and W6B3 to the leukemic cells in 11/20 AML and 5/6 CML samples was comparable. In contrast, binding of 293C3 was observed in 18/20 AML cases and 5/6 CML cases. This indicates that 293C3 recognizes a particular epitope, which is expressed in a high proportion of AML cases. Therefore mAb 293C3 was selected for generation of chimeric mAbs with either a wildtype Fc part (293C3-WT) or a variant containing distinct modifications (S239D/I332E) to enhance its affinity to the Fc receptor CD16 (293C3-SDIE). The binding specificity of 293C3-WT and 293C3-SDIE was validated in analyses with CD133 transfectants and the respective mock controls. In cytotoxicity assays and analyses of NK cell degranulation, 293C3-WT clearly induced NK cell ADCC against primary leukemia cells. However, ADCC activity of the Fc-optimized mAb 293C3-SDIE markedly exceeded that of its counterpart containing the wild type Fc part. Considering the expression of CD133 on healthy hematopoietic progenitor cells, we presently evaluate potential toxicity of the antibodies towards these cells and other healthy tissue. We envisage that 293C3-SDIE might be an attractive immunotherapeutic reagent for the elimination of minimal residual disease in CD133 expressing leukemia, particularly in the context of allogenic SCT. Citation Format: Samuel Koerner, Julia Leibold, Ludger Grosse-Hovest, Hans-Jörg Bühring, Helmut R. Salih, Gundram Jung. Development and preclinical characterization of an Fc-optimized CD133 antibody for improved induction of NK cell reactivity against myeloid leukemia. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 649. doi:10.1158/1538-7445.AM2014-649
“Sale of organs” to be investigated
Authors: Judy Siegel-Itzkovich
Journal: BMJ (2001)

A committee of experts has been appointed by Israel's health ministry to investigate claims by a Hebrew newspaper of illegal “sales of organs” and other alleged wrongdoings at Tel Aviv's L Greenberg Institute of Forensic Medicine, the country's sole institution for the performance of postmortem examinations in cases of unnatural death.

The ministry's director general, Dr Boaz Lev, named a retired district court judge to head the four member panel, along with others from the ministry, a Beersheba hospital, and the Hebrew University's institute of applied chemistry.

In a weekend magazine cover story in the Yediot Aharonot Daily , reporters Ronen Bergman and Gai Gavra claimed that the institute—headed for the past 13 years by chief pathologist Professor Yehuda …
Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
Authors: Gaurav Goel, Weijing Sun
Journal: Journal of Hematology & Oncology (2015)

Gastrointestinal cancers are a group of highly aggressive malignancies, and novel therapeutic strategies with higher clinical efficacy are being actively sought. ‘Immunotherapy’ is now emerging as one such promising strategy for the treatment of these tumors. This article briefly reviews the recent advances that utilize targeting of immune checkpoint pathways, in the management of gastrointestinal malignancies.
CHLOROMYCETIN IN THE TREATMENT OF TYPHOID FEVER
Authors: L Y JACOBSEN, R A BRODERICK
Journal: Annals of Internal Medicine (1950)

Case Reports1 April 1950CHLOROMYCETIN IN THE TREATMENT OF TYPHOID FEVERLEIF Y. JACOBSEN, RICHARD A. BRODERICKLEIF Y. JACOBSENSearch for more papers by this author, RICHARD A. BRODERICKSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-32-4-775 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptNot many reports on the treatment of typhoid fever with Chloromycetin have been published. Since typhoid fever has become a rare disease in the United States, the opportunity for using this new antibiotic has not often presented itself. The most extensive study published to date was on 10 cases of typhoid fever occurring on the Malayan peninsula and reported by Woodward et al.1 The New England Journal of Medicine in an editorial in the May 1949 issue, summarizes the knowledge of the antibiotic up to that date.A case of typhoid fever was admitted to the Flushing Hospital and treated...Bibliography1. WoodwardSmadelLeyGreenMankikar TEJEHLRDS: Preliminary report on the beneficial effect of Chloromycetin in the treatment of typhoid fever, Ann. Int. Med. 29: 131-134, 1948. LinkGoogle Scholar2. Editorial: Antibiotic therapy in typhoid fever, New England J. Med. 240: 782-784, 1949. CrossrefGoogle Scholar3. CollinsPaineWellsFinland HSTFEBM: Aureomycin—a new antibiotic: Evaluation of its effects on typhoid fever, severe salmonella infections and in a case of colon bacillus bacteremia, Ann. Int. Med. 29: 1077-1092, 1948. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication July 21, 1949. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1950Volume 32, Issue 4Page: 775-777KeywordsAntibioticsTyphoid ePublished: 1 December 2008 Issue Published: 1 April 1950 PDF downloadLoading ...